INFORMATION DISCLOSURE STATEMENT

SHEET

CITE

NO.

OF 2

Complete if known

Application Number: 09/970,843

RECEIVE

Filing Date: October 4, 2001

IIII 3 1 2002

First Named Inventor: Ronald Rubenstein et al.

Group Art Unit: 1614

TECH CENTER 1600/2000

Examiner Name: Not Yet Assigned

Attorney Docket Number: 3460-CHOP-0107

JUL 20002

EXAMINER'S

INITIALS


PATENT NUMBER ISSUE DATE FIRST NAMED INVENTOR MM-DD-YYYY

FOREIGN PATENT DOCUMENTS					
EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT

OTHER PRIOR ART - NON-PATENT DOCUMENTS				
EXAMINER'S INITIALS	is used posicil companium potalog etc.) data paga(a) valuma isaug number(a) nublisher city and/or country wh			
5~	C1	RUBENSTEIN, R.C. et al., "In Vitro Pharmacologic Restoration of CFTR-mediated Chloride Transport with Sodium 4-Phenylbutyrate in Cystic Fibrosis Epithelial Cells Containing F508-CFTR"; J. Clin. Invest., 100(10): 2457-2465 (1997)		
5~	C2	RUBENSTEIN, R.C. et al., "A Pilot Clinical Trial of Oral Sodium 4-Phenylbutyrate (Buphenyl) in ÄF508-Homozygous Cystic Fibrosis Patients"; Am. J. Respir. Crlt Care Med., 157: 484-490 (1998)		
5~	С3	BROWN, C.R. et al., "Chemical chaperones correct the mutant phenotype of the ÄF508 cystic fibrosis transmembrane conductance regulator protein"; Cell Stress & Chaperones, 1(2): 117-125 (1996)		
5.v	C4	EIDELMAN, O. et al., "A₁ adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells"; Proc. Natl. Acad. Sci. USA, 89: 5562-5566 (1992)		
52	C5	DALEMANS, W. et al., "Altered chloride ion channel kinetics associated with the ÄF508 cystic fibrosis mutation"; Nature, 354: 526-528 (1991)		
(L	C6	CHENG, S.H. et al., "Functional activation of cystic fibrosis trafficking mutant ÄF508-CFTR by overexpression"; Am. J. Physiol., 258 (Lung Cell. Mol. Physiol. 12): L615-L624 (1995)		
5~	C7	HWANG, T. et al., "Genistein potentiates wild-type and ÄF508-CFTR channel activity"; Am. J. Physiol. 273 (Cell Physiol. 42): C988-C998 (1997)		
5	C8	DENNING, G.M. et al.; "Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive"; Nature, 358: 761-764 (1992)		

			
EXAMINER'S	1 -	DATE	10-16-07
SIGNATURE	5.0	CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.



5~	C9	HE, Z. et al., "Cystic fibrosis transmembrane conductance regulator activation by cAMP-independent mechanisms"; Am. J. Physiol. 275 (Cell Physiol. 44): C958-C966 (1998)	
5~	. C10	DRUMM, M.L. et al., "Chloride Conductance Expressed by ÄF508 and Other Mutant CFTRs in <i>Xenopus</i> Oocytes"; Science, 254: 1797-1799 (1991)	
5~	C11	CHENG, S.H. et al., "Defective Intracellular Transport and Processing of CFTR Is the Molecular Basis of Most Cystic Fibrosis"; Cell, 63: 827-834 (1990)	
(~	C12	WARD, C.L., et al., "Intracellular Turnover of Cystic Fibrosis Transmembrane Conductance Regulator"; The Journal of Biological Chemistry, 269(41): 25710-25718 (1994)	
5~	C13	SATO, S. et al., "Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis Mutation"; The Journal of Biological Chemistry, 271(2): 635-638 (1996)	
5~	C14	LAMARTINIERE, C.A., et al., "Genistein suppresses mammary cancer in rats"; Carcinogenesis, 16(11): 2833-2840 (1995)	
5~	C15	GRAY, G.E. et al., "Breast-Cancer Incidence and Mortality Rates in Different Countries in Relation to Known Risk Factors and Dietary Practices"; Br. J. Cancer 39: 1-7 (1979)	
5~	C16	SEVERSON, R.K., et al., "A Prospective Study of Demographis, Diet, and Prostate Cancer among Men of Japanese Ancestry in Hawaii"; Cancer Research, 49: 1857-1860 (1989)	

EXAMINER'S		DATE	19/11/25
SIGNATURE	5. 6	CONSIDERED	() (6 / 8)